introduction least since famous article powerful placebo beecher scientifically acknowledged placebo pill intervention beneficial effect consequently placebo may represent control condition randomized controlled study pharmacological research also considered respect therapeutic goal today significant impact placebo shown wide variety condition symptom unfortunately deception placebo believed crucial element placebo effect resulting severe ethical problem e.g. undermining consent trust patient healthcare provider trying administer placebo recently idea give placebo without deception would considered ridiculous intriguing new evidence demonstrates open-label placebo olps may help patient various clinical disorder even individual nonclinical symptom thus effect olps shown several different condition including example irritable bowel syndrome depression pain anxiety emotional distress furthermore reported olps may reduce symptom allergic rhinitis however olp study represent two-arm study usually olp treatment-as-usual tau condition problematic possible different handling group although formal patient-experimenter interaction may identical group experimenter might unconsciously focused participant olp group thereby providing support given olp trial obviously blinded participant know hypothesis study report self-report data response bias might consequence subliminal interaction blinded experimenter additional control condition conventional placebo would help address problem could also help answer question efficacy olp treatment thus reported effect size olp intervention usually based comparison tau condition known whether effect size olp similar lower higher conventional double-blind placebo assumption may justified since mechanism olp might different conventional placebo also important ass potential impact olps possible practical implication present study intended address gap aimed test efficacy olp approach relative double-blind placebo tau thus conducted randomized-controlled trial effect olps symptom seasonal allergic rhinitis allergic rhinitis affect population developed world associated high economic burden defined condition caused hypersensitivity immune system driven immunoglobulin ige -mediated reaction upper respiratory system symptom seasonal allergic include example sneezing rhinorrhea itching eye although effective treatment immunotherapy treatment symptomatic relief known often completely resolve symptom furthermore expensive related side effect given symptom allergic rhinitis vary depending seasonal change high low allergic load environment waxing waning characteristic allergic symptom consequently placebo effect symptomatic therapy well-known current study included patient seasonal allergic symptom week trial tested whether olp treatment superior tau compare efficacy conventional double blind placebo condition result help ass impact olp treatment material method participant springtime springtime screened patient eligibility patient excluded meeting inclusion criterion reason e.g. show second measurement see flowchart fig table show demographic detail participant recruitment used flyer social medium local university study stopped spring due covid-19 pandemic continued spring included patient participated pandemic figure patient flow diagram result drug part prob study reported separate publication full size image table demographic baseline characteristic mean standard deviation full size table study registered clinical trial drks00015804 registered 2/11/2018 patient provided written informed consent participating study inclusion criterion study medical record allergic rhinitis age year exclusion criterion medical history diabetes gastrointestinal disease use antibiotic medication last week pregnancy psychiatric neurological history perennial allergic rhinitis chronic rhinosinusitis chronic nasal condition anatomical alteration e.g. septum deviation perforation determine sample size considered previous study allergic symptom detail see study protocol power calculation resulted total sample size desired power 0.80 alpha error probability 0.05 account possible drop-outs calculated total sample size participant study design intervention procedure study design consists randomized placebo-controlled four-arm study olp-treatment effect symptom allergic rhinitis olp treatment compared conventional double-blind placebo arm tau control arm double-blind drug condition probiotic treatment prob see fig result probiotic treatment reported separate publication examines question whether probiotic treatment effect symptom allergic rhinitis current study focused placebo effect investigates impact placebo without concealment however probiotic arm necessary establish double-blind condition study conducted medical school berlin msb berlin germany trial protocol study published used drop placebo condition olp double-blind placebo included carrier solution probiotic treatment lactose-monohydrate glucose-monohydrate drop indistinguishable color smell taste probiotic study announced research psychophysiological interaction treatment seasonal allergic symptom participant informed assigned different group receive probiotic treatment placebo double-blinded fashion olp treatment probiotic treatment offered participant end trial participant received information instruction additional information e.g. olp prob group group assignment signing informed consent patient first completed questionnaire measure allergic symptom see subsequently participant told placebo inactive substance containing medication deceptive well non-deceptive placebo may still powerful explained possible mechanism placebo response may classical conditioning positive attitude may helpful necessary taking placebo faithfully important information analogue previous study furthermore explained probiotic also found certain food sauerkraut yoghurt known beneficial effect health subsequently randomized participant one four arm study opening opaque envelope randomization based computer-generated random number sequence independent researcher first arm patient received probiotic treatment week prob second arm identically looking placebo drop double blind placebo dbp given participant prob dbp condition kept secluded broken full evaluation study third arm olp condition patient received placebo told drop placebo last arm treatment-as-usual condition tau condition participant instructed continue usual allergic pharmacological medication dbp olp condition participant instructed take drop three time day olp dbp prob group received instruction information participant asked complete daily diary burden allergic symptom week participant invited second visit blinded experimenter participant completed questionnaire respect allergic burden primary endpoint primary outcome measure combined symptom medication score csms recommended european academy allergy clinical immunology eaaci csms ass allergic symptom including nose eye symptom respect last last two week symptom rated ranging symptom +++ strong symptom thus lower score represent reduced symptom burden also asks use medication patient instructed continue regular medication computed csms without medication score primary endpoint measure quality life measured rhinitis quality life questionnaire rqlq instrument includes question within seven field ass health-related quality life allergic rhinitis activity limitation sleep impairment non-nasal/eye symptom practical problem nasal symptom eye symptom emotional problem participant indicate response likert scale symptom bother symptom bothered extremely lower score indicate improved health related quality life rqlq widely used validated secondary endpoint secondary endpoint measure total nasal symptom score well-known describe symptom allergic rhinitis contrast questionnaire focus nasal symptom participant rate five different nasal symptom e.g. itching sneezing scale symptom difficult bear interfere activity respect last last two week hence lower score reflect symptom well-known validated many language addition asked participant complete daily diary patient use visual-analogue scale measure daily burden allergic symptom general feeling respect allergic symptom consisted long straight line end good bad low score indicate symptom statistical analysis test effect treatment applied generalized estimating equation gee repeated measure gee includes autoregressive correlation structure considers correlation repeated measurement participant furthermore ensure group comparable beginning study tested whether baseline score group different wilcoxon test also tested difference symptom pandemic wilcoxon test diary data analyzed comparing mean first three day mean last three day ethical approval study adhered declaration helsinki approved ethic committee participant gave written informed consent result effect olp allergic symptom baseline data revealed difference respect different arm see table analyzing csms score pre post showed greater improvement olp group compared tau dbp group participant rated symptom past change score olp 1.20 2.41 dbp 0.25 2.65 tau 0.42 2.39 gee model wald 14.32 0.014 0.46 see fig similar result shown participant evaluate last week gee wald 17.13 0.004 0.50 see table result rqlq also showed stronger improvement olp olp 0.77 1.09 dbp 0.41 1.36 tau 0.28 0.95 gee wald 18.62 0.002 0.52 figure outcome week endpoint primary outcome measure csms change score pre post bar represent standard error full size image table outcome week endpoint mean standard deviation change score full size table result revealed improved score olp relative dbp tau change score last gee wald 18.58 0.002 0.52 see fig supported score last week result failed reach level significance gee wald 5.06 0.10 0.27 analysis diary data demonstrated effect borderline olp gee wald 11.08 0.05 0.40 figure outcome week endpoint secondary outcome measure change score pre post bar represent standard error full size image followed priori hypothesis performed analysis test whether olp condition superior tau wilcoxon test result revealed olp improved tau csms last two week medium effect size 2.17 0.030 0.31 whereas comparison csms last failed reach level significance 1.40 0.161 0.20 olp also superior medium effect size outcome measure rqlq 2.07 0.038 0.30 tnns â€“2.86 0.004 0.41 week 0.95 0.343 0.14 comparing olp dbp found olp superior dbp respect 2.68 0.007 bonferroni corrected 0.021 0.41 week 0.10 showed trend significance csms 1.67 0.095 corrected 0.10 0.26 week 1.80 0.073 corrected 0.10 0.28 rqlq 0.10 comparison dbp tau revealed significant difference 0.10 daily diary found significant effect 0.10 effect covid-19 allergic symptom treatment since part sample included pandemic onset able compare allergic burden general well impact placebo treatment end pandemic result demonstrated patient showed significantly stronger allergic symptom prior pandemic csms rqlq considering four arm study moreover found impact olp treatment also greater pandemic see table patient dbp group prior pandemic unable ass impact covid-19 effect conventional placebo table comparison allergic symptom covid-19 pandemic baseline data bold data mark significant result wilcoxon test including arm study full size table table comparison olp effect covid-19 pandemic change score bold data mark significant result wilcoxon test olp group full size table discussion present study aimed test efficacy olps relieve symptom allergic rhinitis result showed olp improved symptom dbp tau condition olp effect reported respect different clinical non-clinical symptom usually impact olps compared tau study trying compare effect olp treatment tau also double-blinded placebo condition result replicated previous finding olp treatment symptom allergic rhinitis compared tau contrast previous study show beneficial effect olps based csms questionnaire recommended test change allergic symptom well widely used allows better comparability study furthermore olp group improved health-related quality life rqlq however nasal symptom measured find significant effect asking ass time last week might explained difficulty assessing allergic burden past remarkably found olp effect superior conventionally concealed placebo showed effect compared tau thus surprising see classic placebo effect considering waxing waning characteristic allergic symptom placebo effect allergic rhinitis well-known recent metanalysis revealed seasonal allergic rhinitis placebo response resulted improvement whereas active treatment antihistamine corticosteroid showed 1.56 2.71-fold greater improvement placebo one could speculate absence conventional placebo effect may accounted dosage form possibly kind placebo e.g. pill might induced placebo effect another reason may point group difference respect positive expectation although group received identical instruction expectation may still different olp group received bottle label placebo whereas bottle dbp group placebo probiotic label dbp condition participant took drop relatively long time may thought received treatment rather placebo view may also supported non-sweet taste drop therefore placebo instruction might effect participant future study ask participant end study think actually received present study one first 4-arm study comparing effect open-label concealed placebo locher compared olps conventionally concealed placebo treatment control pain tolerance result showed olps placebo deception differ subjective heat pain intensity unpleasantness rating lembo compared effect olps tau conventionally concealed placebo patient irritable bowel syndrome found olp superior tau improving symptom similar effect placebo deception result supplement result demonstrating olp even better dbp result suggest way olps work may different compared mechanism dbp example expectancy often used explain conventional placebo effect recent research suggests mechanism may account olp effect e.g. although exact mechanism olp effect remain cleared one could speculate mechanism seem important olps mechanism may distinguish olp dbp treatment however based present data feel unable address mechanism olps detail could replicate olp effect symptom seasonal allergic rhinitis recent study find effect olps patient several difference might account lack effect first study kube provided olp remotely thus personal interaction reduced using online way communicate perform measurement second point may even important kube conducted study covid-19 pandemic may influential way may covid-19 pandemic affected result present study included patient end pandemic allowing compare general allergic symptom baseline data also efficacy olp effect pandemic result demonstrate allergic symptom general reduced covid-19 pandemic line recent study reason improvement symptom may reduced confrontation allergic pollen lock-down situation due obligation wearing mask public addition psychological factor may explain finding since nose related symptom allergy similar covid-19 symptom individual may neglected symptom want think chance infected virus general allergic symptom affected also found olp effect weaker covid-19 pandemic although consider comparison based relatively participant one could speculate individual covid-19 pandemic might prone olp effect example psychological reason might explain difference see furthermore smaller olp effect may explained statistical effect reduced baseline allergic symptom covid-19 pandemic may given opportunity show improvement unfortunately sufficient data ass impact covid-19 pandemic concealed placebo observed significant effect olps allergic symptom using csms olps showed weak effect diary data one explanation might diary data ask score situation general way contrast csms ask specific symptom previous study found effect also diary data asking specifically allergic symptom interestingly recent study olp effect allergy symptom observed pronounced effect participant asked rate frequency rather severity symptom current study similarly found highest effect size doe ask symptom severity directly csms doe remarkably found weakest result diary data asked general feeling respect allergic may interpreted rating severity symptom difference may point importance way ass self-report data olp study limitation study mentioned data current study relies self-report questionnaire given olp treatment administered double blinded way response bias might problem although tried address issue adding conventional placebo condition study needed ass impact olps particular study using physiological data source could help test impact olps allergic symptom example leibowitz examined physiological allergic reaction histamine skin prick test found effect olp participant strong belief placebo furthermore future study needed replicate finding using example increased sample size present study aimed test efficacy olp patient seasonal allergic rhinitis result demonstrated olps improved self-reported allergic symptom 4-week trial whereas conventional placebo failed show effect result point different mechanism placebo treatment conclude result encourage research effect olps